Pharmacol Res Perspect. 2022 Dec;10(6):e01029. doi: 10.1002/prp2.1029.
NO ABSTRACT
PMID:36468400 | DOI:10.1002/prp2.1029
Categories
Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
